ViroLogic to Host Third Quarter 2004 Financial Results Conference Call on Monday, November 15, 2004 at 8:30 a.m. ET
12 November 2004 - 4:28AM
PR Newswire (US)
ViroLogic to Host Third Quarter 2004 Financial Results Conference
Call on Monday, November 15, 2004 at 8:30 a.m. ET SOUTH SAN
FRANCISCO, Calif., Nov. 11 /PRNewswire-FirstCall/ -- ViroLogic,
Inc. (NASDAQ:VLGC) announced that it will hold a conference call on
Monday, November 15, 2004 at 8:30 a.m. ET to discuss third quarter
2004 financial results. The call will be hosted by Mr. William D.
Young, Chairman & CEO of ViroLogic, Inc. To participate in the
teleconference please call 1-866-800-8652 fifteen minutes before
the conference begins. International callers please dial
617.614.2705. The participant passcode is 22871658. A replay of the
call will also be available at (888) 286-8010 or 617-801-6888 for
international callers, until November 26. The replay passcode is
39389010. The call will also be webcast live at
http://www.virologic.com/. Please see web site for details. About
ViroLogic ViroLogic is a biotechnology company advancing
individualized medicine by discovering, developing and marketing
innovative products to guide and improve treatment of serious viral
diseases such as AIDS and hepatitis. The Company's products are
designed to help doctors optimize treatment regimens that lead to
better patient outcomes and reduced costs. ViroLogic's technology
is also being used by numerous biopharmaceutical companies to
develop new and improved anti-viral therapeutics and vaccines
targeted at emerging drug-resistant viruses. More information about
the Company and its technology can be found on its website at
http://www.virologic.com/ . Forward Looking Statements Certain
statements in this press release are forward-looking. These
forward-looking statements are subject to risks and uncertainties
and other factors, which may cause actual results to differ
materially from anticipated results or expectations and include,
but are not limited to, the timing of customer clinical trials,
risks related to our pending merger with ACLARA, including the risk
that the closing conditions of the merger may not be satisfied and
the merger may not be completed, and costs related to the proposed
merger may adversely impact ViroLogic's financial performance
and/or condition, the risks that the Company's products may not
perform, whether ViroLogic successfully introduces new products,
risks related to the implementation of the Company's distribution
agreement with Quest Diagnostics, whether others introduce
competitive products, the risk that the Company's products may not
continue to be accepted or that increased demand may not develop as
anticipated, the risk that gross margins may not increase as
expected, whether payors will authorize reimbursement for its
products, whether the FDA or any other agency will decide to
regulate ViroLogic's products or services, whether the Company will
encounter problems or delays in automating its processes, whether
intellectual property underlying the Company's technology is
adequate, whether licenses to third party technology will be
available, and whether ViroLogic will be able to raise sufficient
capital when required. For a discussion of these and other factors
that may cause ViroLogic's actual events to differ from those
projected, please refer to the Company's most recent annual report
on Form 10-K, quarterly reports on Form 10-Q, and the amended Joint
Proxy/Prospectus related to the proposed merger with ACLARA, as
well as other subsequent filings with the Securities and Exchange
Commission. DATASOURCE: ViroLogic, Inc. CONTACT: Investor Relations
of ViroLogic, Inc., +1-650-635-1100 Web site:
http://www.virologic.com/
Copyright
Virologic (NASDAQ:VLGC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Virologic (NASDAQ:VLGC)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Virologic (MM) (NASDAQ): 0 recent articles
More Virologic (MM) News Articles